5.11
0.44 (9.42%)
| Penutupan Terdahulu | 4.67 |
| Buka | 4.65 |
| Jumlah Dagangan | 525,171 |
| Purata Dagangan (3B) | 247,516 |
| Modal Pasaran | 210,519,584 |
| Harga / Jualan (P/S) | 101.14 |
| Harga / Buku (P/B) | 172.55 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| Margin Operasi (TTM) | -3,917.27% |
| EPS Cair (TTM) | -3.47 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -27.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.68% |
| Nisbah Semasa (MRQ) | 3.67 |
| Aliran Tunai Operasi (OCF TTM) | -67.20 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -48.03 M |
| Pulangan Atas Aset (ROA TTM) | -135.31% |
| Pulangan Atas Ekuiti (ROE TTM) | -263.65% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Instruments & Supplies (US) | Menaik | Bercampur |
| Medical Instruments & Supplies (Global) | Menaik | Menurun | |
| Stok | Anteris Technologies Global Cor | Bercampur | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.75 |
|
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. |
|
| Sektor | Healthcare |
| Industri | Medical Instruments & Supplies |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.21% |
| % Dimiliki oleh Institusi | 64.12% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| L1 Capital Pty Ltd | 30 Sep 2025 | 6,838,136 |
| Rhenman & Partners Asset Management Ab | 30 Sep 2025 | 1,250,763 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 17 Nov 2025 | Pengumuman | Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves |
| 12 Nov 2025 | Pengumuman | Anteris Announces Results for the Third Quarter of 2025 |
| 03 Nov 2025 | Pengumuman | FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”) |
| 28 Oct 2025 | Pengumuman | Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year |
| 27 Oct 2025 | Pengumuman | Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”) |
| 27 Oct 2025 | Pengumuman | Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |